Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Dec 22 2022 | Top Takeways in HF Science of 2022 Explored in Two-Part Series of HF Beat Podcast HFSA News Podcasts Provider Education Read More Dec 18 2022 | HFSA President's Update: December 2022 HFSA News President's Updates Read More Dec 14 2022 | Cytokinetics Announces Outcome of FDA Advisory Committee Vote on Omecamtiv Mecarbil Industry News In The News Industry Read More Dec 13 2022 | The Intersection of Diabetes, Chronic Kidney Disease and Heart Failure Patient News Heart Failure Awareness 365 Patient Resource Read More Dec 8 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 53 Page 54 Page 55 Page 56 Current page 57 Page 58 Page 59 Page 60 Page 61 … Next page Next › Last page Last »
Dec 22 2022 | Top Takeways in HF Science of 2022 Explored in Two-Part Series of HF Beat Podcast HFSA News Podcasts Provider Education Read More
Dec 14 2022 | Cytokinetics Announces Outcome of FDA Advisory Committee Vote on Omecamtiv Mecarbil Industry News In The News Industry Read More
Dec 13 2022 | The Intersection of Diabetes, Chronic Kidney Disease and Heart Failure Patient News Heart Failure Awareness 365 Patient Resource Read More
Dec 8 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Industry News In The News Industry Read More
